The online drug reference for healthcare professionals, Monthly Prescribing Reference, published a 2011 warning to users of oral contraceptives containing the chemical drospirenone, such as YAZ®. Here is what was said:
“Two studies did not report any difference in VTE risk” (VTE risk is the risk of developing a possibly-mobile deep-vein blood clot) “between drospirenone-containing products and products containing levonorgestrel or other progestins. Two publications from 2009, however, reported a 1.5- to 2-fold higher VTE risk with drospirenone-containing contraceptives as compared with levonorgestrel-containing contraceptives while two articles published in 2011 reported a 2- to 3-fold greater risk of VTE.”[1] (emphasis added)
VTE is a very serious condition. If a blood clot becomes lodged in the heart, one can have a heart attack. If a blood clot becomes lodged in the brain, one can have a stroke. Because of this report’s clear sentiment that drugs containing drospirenone, such as YAZ®, have been found to be more dangerous than other hormonal contraceptives, a Yaz lawyer can make use of this article in effort to provide convincing evidence to court that YAZ® unnecessarily places women at higher risk for adverse health effects, given YAZ® is no more effective than other similar drugs.
[1] “SAFETY ALERT: FDA Provides Safety Update on Increased VTE Risk with Drospirenone-Containing Oral Contraceptives – MPR” Monthly Prescribing Reference. September 27, 2011. © 2012 Haymarket Media, Inc. Available at <http://www.empr.com/safety-alert-fda-provides-safety-update-on-increased-vte-risk-with-drospirenone-containing-oral-contraceptives/article/212912/> accessed 8 October 2012
Comments